Skip to content

The Future Use of Real-World Evidence

The Future Use of Real-World Evidence

July 10th, 2018

Washington Marriott Georgetown

1221 22nd St NW

Washington, DC 20037

Thank you all who attended our past event! The meeting whitepaper, Establishing a Framework to Evaluate Real-World Endpoints, has been officially released. All videos from the event can now be viewed on our YouTube page hereCheck out our Engaging Innovation Blog for a full event recap. In the meantime we will be linking meeting slides below in the agenda as they become available.

Friends of Cancer Research (Friends) is proud to announce a public meeting involving multiple stakeholders across industry, Real-World Evidence (RWE) data partners, FDA, academics, and research and advocacy organizations. The meeting will include results from a pilot study determining how endpoints generated from real-world data correlate with overall survival and other key measures. Panels will discuss policies related to the use of RWE, as well as provide vital information about the long-term value of a product including its safety and efficacy.

A draft agenda is provided below. For more information on the meeting topic, please click HERE.

Finalized Agenda

8:30am – Registration and Breakfast

9:00am – Opening Remarks

  • Ellen Sigal, Friends of Cancer Research

9:00am – Pilot project data: Correlation of real-world endpoints to overall survival among immune checkpoint inhibitor-treated aNSCLC patients

  • Jeff Allen, Friends of Cancer Research

9:20am – Panel 1: Assessment and reaction to pilot project results

Moderator: Elad Sharon, National Cancer Institute

  • Amy Abernethy, Flatiron Health
  • Andrew Norden, Cota
  • Elizabeth Chrischilles, UIowa/PCORnet
  • Henry Joe Henk, Optum Labs
  • Larry Kushi, Kaiser Permanente/CRN
  • Nancy Dreyer, IQVIA

10:05am – Q&A with audience

10:35am – Break

10:55am – Real-world evidence to supplement clinical trial data

  • Gideon Blumenthal, U.S. Food and Drug Administration (FDA)
  • Pallavi Mishra-Kalyani, FDA

11:15am – Panel 2: Applying real-world endpoints to oncology drug development and regulatory decision-making

Moderator: Michael Maitland, Inova Center for Personalized Health and Inova Schar Cancer Institute

  • Eric Rubin, Merck & Co.
  • John Penrod, Bristol-Myers Squibb
  • Michael Taylor, Genentech
  • Pallavi Mishra-Kalyani, FDA
  • Sean Khozin, FDA

12:00pm – Q&A with audience

12:30pm – Lunch

1:30pm – Panel 3: Regulatory and policy implications of real-world endpoints

Moderator: Michael McCaughan, Prevision Policy

  • Jane Perlmutter, Gemini Group
  • Janet Woodcock, FDA
  • Jason Spangler, Amgen
  • Jennifer Malin, United Healthcare
  • Joe Selby, PCORI

2:30pm – Q&A with audience

3:00pm – Closing Remarks

  • Jeff Allen, Friends of Cancer Research​

For more information, contact Heather Chaney at or (202) 944-6719.